Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMPVDQ3)

Drug Name

Milademetan Drug Info

Synonyms

Milademetan; 1398568-47-2; DS-3032; MDM2 inhibitor DS-3032; R3I80TLN7S; DS-3032B; DS3032; 2,6-Anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide; L-Erythro-hexonamide, 2,6-anhydro-5-((((3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-; L-erythro-Hexonamide, 2,6-anhydro-5-[[[(3'R,4'S,5'R)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'',2''-dihydro-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-[3H]indol]-5'-yl]carbonyl]amino]-3,4,5-trideoxy-; MILADEMETAN [INN]; MILADEMETAN [USAN]; UNII-R3I80TLN7S; MILADEMETAN [WHO-DD]; RAIN-32; DS3032b; CHEMBL4292264; SCHEMBL12527208; GTPL12941; RYAYYVTWKAOAJF-QISPRATLSA-N; EX-A6155; YFC56847; BDBM50467678; NSC800893; AKOS040733738; DB15257; NSC-800893; MS-30758; HY-101266; CS-0021065; Q27896170; (3'R,4'S,5'R)-N-((3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl)-6''-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-indole)-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyloxan-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide; (3'R,4'S,5'R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Liposarcoma	2B59	Phase 3	[1]

Cross-matching ID

PubChem CID: 73297272
TTD Drug ID: DMPVDQ3

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor VIII (F8)	TT1290U	FA8_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Coagulation factor VIII (F8)	DTT	F8	7.637	6.9	7.644	6.975

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Liposarcoma

ICD Disease Classification

2B59

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Coagulation factor VIII (F8)	DTT	F8	1.08E-22	0.89	1.82

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04979442) A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients With Dedifferentiated Liposarcoma. U.S.National Institutes of Health.
2	A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021 Oct 7;138(14):1258-1268.